Bioniche in talks to boost cash reserves
09 May, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) is in talks with its lender to address a looming cash shortage and consulting with advisers to address the “challenges” posed by a group of dissident shareholders.
Concern over NSW indemnity insurance impact on clinical trials prompts survey
09 May, 2013Members of AusBiotech are invited to participate in a survey to gauge the impact of the 2011 increase in the Clinical Trial Indemnity Insurance Compliance Requirement.
New member for Prima board
09 May, 2013 by Susan Williamson and Dylan Bushell-EmblingPrima Biomed (ASX: PRR) has announced a new board member, Dr Russell Howard.
Iluvien launches in Germany
08 May, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera Sciences has followed up the launch of DME treatment Iluvien in the UK with the first commercial sale in Germany.
Novogen appoints new CSO
07 May, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has announced two new executive appointments - a CSO, as well as a president and CEO of its new North American subsidiary.
Submission to reduce clinical trial insurance in NSW
07 May, 2013 by Susan WilliamsonContributions are being sought for a submission to NSW Health to reduce clinical trial indemnity insurance in the state.
Japan’s I’rom buys into IDT Australia
07 May, 2013 by Dylan Bushell-EmblingJapanese site management organisation (SMO) I’rom Holdings will pay $2m for a 19% stake in CMO IDT Australia, and the pair will combine their clinical trial site offerings in Australasia.
David Penington to headline AusMedtech Melbourne conference dinner
07 May, 2013Emeritus Professor David Penington AC will deliver an insightful address about his experiences within the medical industry and how to translate medical research into products as part of the AusMedtech 2013 conference dinner on Wednesday 15 May 2013.
Novogen finds new anticancer candidates
07 May, 2013 by Dylan Bushell-EmblingNovogen’s (ASX:NRT) anticancer program has identified two second-generation drug candidates, showing promise in pancreatic cancer and melanoma, and one will be fast-tracked to the clinic.
CardioCel studies presented at medical conferences
06 May, 2013 by Dylan Bushell-EmblingData from studies involving Allied Healthcare’s (ASX:AHZ) CardioCel technology in cardiovascular repair and stem cell growth were presented at two recent medical meetings.
Public companies must monitor social media
03 May, 2013 by Dylan Bushell-EmblingNew ASX disclosure guidelines on monitoring social media for leaks of market-sensitive information herald a new era of reporting compliance, according to Buchan Consulting.
Govt taking applications for precincts initiative
03 May, 2013 by Dylan Bushell-EmblingThe Australian life science industry has a chance to apply to be one of up to 10 Industry Innovation Precincts - consortia of businesses and universities aimed at fostering R&D and competitiveness.
Biotron releases more data from HCV trial
02 May, 2013 by Dylan Bushell-EmblingBiotron has presented some pharmacokinetic data from its phase IIa trial of BIT225 in HCV, showing no evidence of drug resistance growth.
pSivida partner gets new PDUFA date for Iluvien
02 May, 2013 by Dylan Bushell-EmblingThe US FDA will decide by 17 October whether to approve pSivida (ASX:PVA) licensee Alimera’s NDA for Iluvien in diabetic macular edema.
Concern over plan to remove or limit patent extensions
02 May, 2013AusBiotech has made a submission in response to the Pharmaceutical Patent Review’s (PPR) Draft Report, stating its disappointment at the options provided under recommendation 5 to remove or reduce Australia’s patent extension provisions.
